Arizona Senate ad hoc committee held an informational hearing on access to FDA breakthrough psychedelic mental-health therapies, featuring veterans and clinicians who argued for state preparedness, expanded Right to Try access, and additional funding for clinical trials. Presenters described trial results, clinical safeguards, and barriers from federal scheduling and DEA processes.